Cargando…
JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of...
Autores principales: | Lo, Miao-Chia, Peterson, Luke F., Yan, Ming, Cong, Xiuli, Hickman, Justin H., DeKelver, Russel C., Niewerth, Denise, Zhang, Dong-Er |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987672/ https://www.ncbi.nlm.nih.gov/pubmed/23812420 http://dx.doi.org/10.1038/leu.2013.197 |
Ejemplares similares
-
The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling
por: Stoner, Samuel A., et al.
Publicado: (2020) -
Cooperation between RUNX1-ETO9a and Novel Transcriptional Partner KLF6 in Upregulation of Alox5 in Acute Myeloid Leukemia
por: DeKelver, Russell C., et al.
Publicado: (2013) -
Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011) -
Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014) -
Single-cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction
por: Xiong, Qian, et al.
Publicado: (2020)